
Cancel anytime
- Chart
- Upturn Summary
- Highlights
- Revenue
- Valuation
Upturn AI SWOT
- About


Generation Bio Co (GBIO)



- BUY Advisory
- SELL Advisory (Profit)
- SELL Advisory (Loss)
- Profit
- Loss
- Pass (Skip investing)


(see disclosures)
- ALL
- YEAR
- MONTH
- WEEK
Upturn Advisory Summary
08/14/2025: GBIO (1-star) has a low Upturn Star Rating. Not recommended to BUY.
1 Year Target Price $80.5
1 Year Target Price $80.5
3 | Strong Buy |
1 | Buy |
3 | Hold |
0 | Sell |
0 | Strong Sell |
Analysis of Past Performance
Type Stock | Historic Profit -6.81% | Avg. Invested days 24 | Today’s Advisory Consider higher Upturn Star rating |
Upturn Star Rating ![]() ![]() | Upturn Advisory Performance ![]() | Stock Returns Performance ![]() |
![]() ![]() | ![]() ![]() |
Key Highlights
Company Size Small-Cap Stock | Market Capitalization 44.86M USD | Price to earnings Ratio - | 1Y Target Price 80.5 |
Price to earnings Ratio - | 1Y Target Price 80.5 | ||
Volume (30-day avg) 7 | Beta 2.67 | 52 Weeks Range 3.00 - 29.40 | Updated Date 08/15/2025 |
52 Weeks Range 3.00 - 29.40 | Updated Date 08/15/2025 | ||
Dividends yield (FY) - | Basic EPS (TTM) -10.84 |
Analyzing Revenue: Products, Geography and Growth
Revenue by Products
Earnings Date
Report Date 2025-08-06 | When - | Estimate -0.2783 | Actual -3.0445 |
Profitability
Profit Margin - | Operating Margin (TTM) -2928.37% |
Management Effectiveness
Return on Assets (TTM) -20.95% | Return on Equity (TTM) -85.45% |
Valuation
Trailing PE - | Forward PE - | Enterprise Value -11180277 | Price to Sales(TTM) 2.11 |
Enterprise Value -11180277 | Price to Sales(TTM) 2.11 | ||
Enterprise Value to Revenue 5.1 | Enterprise Value to EBITDA -0.34 | Shares Outstanding 6735540 | Shares Floating 4936952 |
Shares Outstanding 6735540 | Shares Floating 4936952 | ||
Percent Insiders 14.24 | Percent Institutions 65.22 |
Upturn AI SWOT
Generation Bio Co

Company Overview
History and Background
Generation Bio Co. was founded in 2016 and is a biotechnology company focused on developing genetic medicines for liver and other disorders. The company is pioneering a gene therapy platform based on closed-ended DNA (ceDNA), aiming to overcome limitations of existing gene therapies.
Core Business Areas
- Genetic Medicine Development: Focuses on developing gene therapies for a range of diseases, including liver, lung, and ophthalmic disorders using its proprietary ceDNA platform.
- ceDNA Platform Technology: Developing and refining its closed-ended DNA (ceDNA) platform to enable durable, redosable gene therapies.
Leadership and Structure
The leadership team includes Philippe Leboulch, MD, as Chief Executive Officer. The organizational structure includes research and development, clinical operations, and business development departments.
Top Products and Market Share
Key Offerings
- GBT001 (Phenylketonuria Program): A ceDNA-based gene therapy candidate for phenylketonuria (PKU). The drug is in preclinical stage. Key competitors include BioMarin Pharmaceutical (KUVAN and PALYNZIQ) and Homology Medicines (gene editing approach).
- Hemophilia A Program: A ceDNA-based gene therapy candidate for hemophilia A. The drug is in preclinical stage. Key competitors include BioMarin (ROCTAVIAN) and CSL Behring (gene therapy programs).
Market Dynamics
Industry Overview
The gene therapy market is rapidly growing, driven by advancements in delivery technologies and increasing regulatory approvals. It is a competitive landscape with many pharma and biotech companies focusing on different targets and technologies.
Positioning
Generation Bio is positioned as an innovator in the gene therapy space, focusing on developing redosable and durable therapies based on its ceDNA technology. This could provide a competitive advantage over viral vector-based therapies.
Total Addressable Market (TAM)
The global gene therapy market is projected to reach USD 25 billion by 2027. Generation Bio is positioned to capture a portion of this TAM through its innovative ceDNA platform.
Upturn SWOT Analysis
Strengths
- Proprietary ceDNA technology
- Potential for redosable gene therapies
- Strong preclinical data
- Experienced leadership team
Weaknesses
- Early stage of development
- High cash burn rate
- Reliance on a single technology platform
- Lack of approved products
Opportunities
- Partnerships with larger pharmaceutical companies
- Expansion into new therapeutic areas
- Advancements in delivery technologies
- Regulatory approvals for gene therapies
Threats
- Competition from established gene therapy companies
- Clinical trial failures
- Regulatory hurdles
- Patent disputes
Competitors and Market Share
Key Competitors
- BMRA
- SRPT
- VRTX
- BLUE
Competitive Landscape
Generation Bio differentiates itself through its ceDNA technology, which aims to address limitations of existing gene therapies. However, it faces strong competition from established players.
Growth Trajectory and Initiatives
Historical Growth: Historical growth is characterized by expansion of research and development programs and advancements in ceDNA technology.
Future Projections: Future growth is dependent on successful clinical trials and potential partnerships. Analyst projections vary widely.
Recent Initiatives: Recent initiatives include advancing preclinical programs into clinical trials and exploring new therapeutic areas.
Summary
Generation Bio is a promising early-stage biotech company with innovative ceDNA technology. While the technology holds great potential and preclinical data is encouraging, it is still in the early stages of development and faces significant clinical and regulatory risks. The company needs to successfully navigate clinical trials and secure partnerships to realize its full potential. Significant cash burn and competition remain critical challenges.
Peer Comparison
Sources and Disclaimers
Data Sources:
- Company website
- SEC filings
- Analyst reports
- Industry publications
Disclaimers:
The information provided is for informational purposes only and should not be considered financial advice. Market share data are estimates and may not be precise. Investing in biotech companies involves significant risks.
AI Summarization is directionally correct and might not be accurate.
Summarized information shown could be a few years old and not current.
Fundamental Rating based on AI could be based on old data.
AI-generated summaries may have inaccuracies (hallucinations). Please verify the information before taking action.
About Generation Bio Co
Exchange NASDAQ | Headquaters Cambridge, MA, United States | ||
IPO Launch date 2020-06-12 | President, CEO & Director Dr. Cameron Geoffrey McDonough M.D. | ||
Sector Healthcare | Industry Biotechnology | Full time employees 115 | Website https://generationbio.com |
Full time employees 115 | Website https://generationbio.com |
Generation Bio Co., a biotechnology company, discovers, develops, and commercializes redosable therapeutics that reprogram T cells in vivo to reduce or eliminate the production and persistence of autoreactive T cells. It develops cell-targeted lipid nanoparticles (ctLNP) to selectively deliver small interfering RNA (siRNA) T cells to selectively delivery, intracellular, and genetically precise mechanism of target engagement could unlock a series of high-value historically undruggable disease-driving genes in autoimmunity. The company was formerly known as Torus Therapeutics, Inc. and changed its name to Generation Bio Co. in November 2017. Generation Bio Co. was incorporated in 2016 and is headquartered in Cambridge, Massachusetts.

Note: This website is maintained by Upturn Corporation, which is an investment adviser registered with the U.S. Securities and Exchange Commission. Such registration does not imply a certain level of skill or training. Investing in securities has risks. Past performance is no guarantee of future returns. No assurance is provided as to any particular investment return, and you may lose money using our services. You are strongly advised to consult appropriate counsel before making any investments in companies you learn about through our services. You should obtain appropriate legal, tax, investment, accounting, and other advice that takes into account your investment portfolio and overall financial situation. You are solely responsible for conducting due diligence on a potential investment. We do not affect trades for you. You will select your own broker through which to transact. Investments are not FDIC insured, they are not guaranteed, and they may lose value. Please see the Privacy Policy, Terms of Use, and Disclosure for more information.